|Last Price||Today's Change||52-Week Range||Trading Volume|
|49.46||0.35 (+0.71%)||39.18 - 57.49||6.7 million (Below Avg)|
Market data as of 4:01PM 04/17/14. Quotes are delayed by at least 15 min.
Bristol-Myers Squibb Presents Phase III Data Demonstrating that Investigational All-oral Daclatasvir and Asunaprevir Therapy Achieved SVR12 Rates of up to 90% Among Broad Range of Genotype 1b Hepatitis C Patients
04/10/2014 7:00 AM ET